Main Industry
Biotechnology
Main Product/Service
i-OBM develops innovative drug formulations using existing active ingredients, focusing on enhancing efficacy, reducing side effects, and extending drug half-life through advanced delivery systems. Their technologies include chelating complex micelles, tr
Founded Year
2011
Unified Business No.
29184891
Status
Active
Number of Employees
0
Total Paid-in
Capital
668,080,000 (NT$)
Location of Company
Taiwan
, Tainan City
Exit Status
Emerging Stock Exchange(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Original BioMedical focuses on developing new drug forms, dosages, and indications without introducing new active ingredients. Their platform can modify a drug’s half-life, enhance efficacy, and reduce side effects, enabling repurposing of existing drugs to shorten development time and revive near-failure compounds. They handle lab-scale synthesis, purification, method and dosage form development, and preclinical testing, while formal preclinical and clinical production is conducted at cGMP-certified manufacturing facilities.
